To include your compound in the COVID-19 Resource Center, submit it here.

UCB adding Ra’s rare immunology assets in $2.5B takeout

Acquiring Ra helps UCB build rare disease immunology franchise, adds Boston-area research hub

UCB is looking to build its rare disease immunology franchise through its proposed $2.5 billion acquisition of Ra Pharmaceuticals -- a price that more than doubles the biotech’s valuation.

The deal would give UCB S.A. (Euronext:UCB) zilucoplan, a peptide inhibitor of C5. Last week, Ra Pharmaceuticals Inc. (NASDAQ:RARX) started testing the therapy

Read the full 510 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE